BANK VONTOBEL/CALL/REGENERON PHARMACEUTICALS/1250/0.01/20.09.24 Share Price

Warrant

DE000VM2R4A6

Delayed Deutsche Boerse AG 16:04:21 23/05/2024 BST
0.058 EUR -15.94% Intraday chart for BANK VONTOBEL/CALL/REGENERON PHARMACEUTICALS/1250/0.01/20.09.24
Current month+1.47%
1 month-6.76%
Date Price Change
23/05/24 0.058 -15.94%
22/05/24 0.069 +7.81%
21/05/24 0.064 +1.59%
20/05/24 0.063 -3.08%
17/05/24 0.065 +4.84%

Delayed Quote Deutsche Boerse AG

Last update May 23, 2024 at 04:04 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying REGENERON PHARMACEUTICALS, INC.
IssuerLogo Issuer Vontobel Vontobel
WKN VM2R4A
ISINDE000VM2R4A6
Date issued 21/09/2023
Strike 1,250 $
Maturity 20/09/2024 (120 Days)
Parity 100 : 1
Emission price 0.08
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.23
Lowest since issue 0.056
Spread 0.01
Spread %12.82%

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
More about the company

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Regeneron Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
983.8 USD
Average target price
1,042 USD
Spread / Average Target
+5.91%
Consensus